CD20-Targeted CAR T-Cell Therapy Shows Safety, Good Response Rates in B-Cell Non-Hodgkin Lymphoma

Article

A phase 1/2 multicenter study is underway following MB-106’s IND approval.

Results of an ongoing phase 1/2 clinical trial of CD20-targeted CAR T-cell therapy in B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia show good response rates and a favorable safety profile. The findings were presented at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (2022 Tandem Meetings), held in Salt Lake City, Utah, and virtually April 23-26, 2022.

The single-center study, led by Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Research Center, is evaluating MB-106 (Mustang Bio), a fully human, 3rd-generation CD20-targeted CAR T product with both 4-1BB and CD28 costimulatory domains across 4 dose levels: 3.3x105; 1x106; 3.3x106; 1x107 CAR T cells/kg.

Following lymphodepletion with cyclophosphamide and fludarabine, 16 patients were treated. Participants had previously treated R/R lymphoma and had failed at least 1 other treatment prior.

Between December 2019 and July 2021, the 16 participants (12 FL, 2 MCL, 1 CLL, 1 DLBCL)reached all dose levels with no dose-limiting toxicities observed. Notably, cytokine release syndrome (CRS) occurred in 44% of patients (n = 7), of which 4 had grade 1 and 3 had grade 2 (median time to occurrence, 6.5 days), and 1 patient experienced grade 2 immune effector cell-associated neurotoxicity syndrome (ICANS; occurrence on day 12). Although immune effector cell-associated neurotoxicity syndrome is an ongoing challenge, Notably, no grade 3 to 4 CRS or ICANS occurred. In addition, 1 patient experienced grade 3 temporary neuropathic pain, and no cases of tumor lysis syndrome or grade 3 or 4 infections were reported.

Investigators reported an overall response rate (ORR) of 94%, with 62% of patients achieving complete response (CR) and 31% achieving partial response (PR). All but 1 complete response are ongoing as of the data cutoff. Among the 12 patients with follicular lymphoma, ORR was 92% (11/12), CR was 75% (9/12), and PR was 17% (2/12). A PET-negative CR and undetectable measurable residual disease in peripheral blood and bone marrow at day 28 was recorded for the single patient with chronic lymphocytic leukemia; 1 patient with diffuse large B-cell lymphoma recorded a partial response on day 28, with PET imaging on about day 90 showing continued improvement; and 2 patients with mantle cell lymphoma recorded partial responses. Complete response rate was higher (86%) among those who received dose levels 3 or 4. Among the treated patients, 1 has thus far lost CAR-T persistence at day 95 and 2 lost CAR-T engraftment by day 181 and 201, respectively. As of last follow-up (approximately 13 months post-infusion), all other patients continue to have detectable CAR-T cells.

“MB-106 has been demonstrating compelling clinical activity and a favorable safety profile in the ongoing Phase 1/2 trial at Fred Hutch for patients with relapsed or refractory B-NHL and CLL,” said Manuel Litchman, MD, president and chief executive officer of Mustang Bio, in a statement. “Looking ahead, Mustang intends to dose the first patient in a multicenter Phase 1/2 clinical trial evaluating the safety and efficacy of MB-106 for relapsed or refractory B-NHL and CLL under Mustang’s IND this quarter.”

REFERENCES
1. Shadman M, Yeung CCS, Lee SY, et al. High Efficacy and Low Toxicity of MB-106, a Third Generation CD20 Targeted CAR-T for Treatment of Relapsed/Refractory B-NHL and CLL. Presented at: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (2022 Tandem Meetings). April 23-26, 2022; Salt Lake City, UT.
2. Mustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations. News release. Mustang Bio. April 21, 2022. https://www.globenewswire.com/news-release/2022/04/21/2426502/0/en/Mustang-Bio-Announces-Upcoming-MB-106-CD20-Targeted-CAR-T-Data-Presentations.html
Recent Videos
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Chun-Yu Chen, PhD, a research scientist at Seattle Children’s Research Institute
Alexandra Collin de l’Hortet, PhD, the head of therapeutics at Epic Bio
David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI
John Finn, PhD, the chief scientific officer of Tome Biosciences
David Dimmock, MBBS, on a Promising Case Study of Ultra-Rare, AI-Guided, ASO Development
Scott Jeffers, PhD, on The Importance of Precise Reproducibility of AAVs
Related Content
© 2024 MJH Life Sciences

All rights reserved.